Table 2.
Summary of the reported treatment modalities and details for the treatment of acinic cell carcinoma of the breast.
| References | Sex/age | Surgery | therapeutic regimen | Outcome |
|---|---|---|---|---|
| Roncaroli et al. (1996) [10] | F/42 | MRM + ALND | CT | AW (1 year after surgery) |
| Schmitt et al. (2000) [11] | F/79 | MRM + ALND | RT | NED (21 months after surgery) |
| Damiani et al. (2000) [5] | F/42 | MRM | Neo-CT + CT (cyclophosphamide) | AW (5 year after surgery) |
| F/35 | MRM + ALND | Neo-CT + CT (cyclophosphamide) | AW (1 year after surgery) | |
| F/80 | BCS | HT | AW (1 year after surgery) | |
| Coyne et al. (2002) [12] | F/49 | MRM + ALND | Neo-CT + CT (Doxorubicin, cyclophosphamide, methotrexate, and 5-fluorouracil, and after 12 months received an additional course of chemotherapy including mitomycin, mitomycin C and methotrexate and epirubicin due to liver metastases) | Liver metastasis (1 year after surgery) and finally died 3 years after initial diagnosis |
| Peintinger et al. (2004) [13] | F/36 | BCS + ALND | CT + RT | Lung metastases occurred 8 years after surgery, and the patient is currently healthy (2 years after resection of the pulmonary mass) |
| Huo et al. (2011) [14] | F/40 | MRM + ALND | Neo-CT (Paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide) + RT + HT | NED (1 year after surgery) |
| F/30 | BCS + ALND | CT + RT | Bone metastases and died (34 months after the initial diagnosis) | |
| Choh et al. (2012) [15] | F/79 | BCS + SLND | RT | NED (after nine months of treatment) |
| Ripamonti et al. (2013) [16] | F/44 | MRM + SLND | HT | AW |
| Winkler et al. (2013) [10] | F/56 | MRM + SLND | Neo-CT (Four cycles of intensive doses of doxorubicin and paclitaxel) + HT | NED (2 years after surgery) |
| Shingu et al. (2013) [17] | F/41 | BCS + SLND | RT (50 Gy-/25 fractions) + CT (docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 intravenously every 3 weeks for 4 cycles) | NED (3 years after surgery) |
| Zhao et al. (2014) [18] | F/38 | MRM + ALND | CT (6 cycles) | NED (10 months after surgery) |
| Zhong et al. (2014) [19] | F/50 F/40 F/59 F/42 F/56 F/42 F/50 F/61 F/35 F/34 F/46 |
BCS BCS Mastectomy BCS Mastectomy Mastectomy Mastectomy Mastectomy BCS Mastectomy Mastectomy |
CT + RT CT + RT CT CT + RT CT CT CT CT CT + RT CT CT |
NED NED NED NED Lung metastasis NED NED NED NED NED NED |
| Conlon et al. (2016) [20] | F/47 | Bilateral mastectomy + ALND | CT + RT + HT | right internal mammary lymph nodes metastasis and alive with disease 6 years after the initial diagnosis |
| F/49 | BCS | Neo-CT | NED (18 months after surgery) | |
| Kawai et al. (2016) [21] | F/49 | MRM + SLND | CT | DR |
| Kim et al. (2017) [22] | F/40 | BCS | CT + RT | DR |
| F/38 | BCS | CT + RT | NED | |
| F/47 | BCS | CT + RT | NED | |
| F/46 | BCS | CT + RT | NED | |
| Waever et al. (2021) [23] | F/42 | Mastectomy + SLND | Neo-CT (received antenatal doxorubicin and cyclophosphamide, and postpartum paclitaxel) | NED |
| Sarsiat et al. (2022) [24] | F/59 | BCS + SLND | Neo-CT (3 cycles of epirubicin 100 mg/m2, 5-fluorouracil 500 mg/m2, and cyclophosphamide 500 mg/m2 were administered every 21 days, followed by 3 cycles of docetaxel 100 mg/m2) + CT | Peritoneal metastases and finally died |
| Present case | F/47 | Bilateral mastectomy + ALND | Neo-CT (6 cycles of Nab-Paclitaxel 80 mg/m2 were administered every 7 days, 2 cycles of Carboplatin 600 mg and Keytruda 200 mg were administered every 21 days) + CT (4 cycles of Epirubicin 150 mg and Cyclophosphamide 1 g were administered every 21 days, followed by 2 cycles of Nab-Paclitaxel 350 mg and Carboplatin 520 mg were administered every 21 days, meanwhile, 11 cycles of Keytruda 200 mg) + oral capecitabine was maintained (3 g in the morning and at night) for one year | NED (14 months after surgery) |
Note: F, female; M, male; MRM, modified radical mastectomy; ALND, Axillary lymph node dissection; CT, chemotherapy; AW, Alive and well; RT, Radiation therapy; NED, no evidence of disease; Neo-CT, Neoadjuvant chemotherapy; BCS, Breast-conserving surgery; HT, Hormone therapy; SLND, Sentinel lymph node dissection; DR, disease recurrence.